

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Marbocyl P 5 mg Tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance:

Marbofloxacin 5 mg

Excipients:

| Qualitative composition of excipients and other constituents |
|--------------------------------------------------------------|
| Lactose Monohydrate |
| Povidone Crospovidone |
| Liver Powder |
| Yeast powder |
| Silica, colloidal anhydrous |
| Hydrogenated Castor Oil |
| Magnesium Stearate |

Brown-beige spotted, circular divisible tablets.

3. CLINICAL INFORMATION

3.1 Target species

Dogs and cats.

3.2 Indications for use for each target species

In Dogs

The veterinary medicinal product is indicated in the treatment of:

Skin and soft tissue infections (intertrigo, folliculitis, impetigo, furunculosis, cellulitis) caused by susceptible strains.

Lower and upper urinary tract infections (UTI) associated or not with prostatitis or epididymitis caused by susceptible strains. Respiratory tract infections caused by susceptible strains.

In Cats

The veterinary medicinal product is indicated in the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) and upper respiratory tract infections caused by susceptible strains.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs aged less than 12 months, or less than 18 months for giant breeds of dogs.

Not recommended for use in cats aged less than 16 weeks.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Not applicable.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

| | |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Very rare (<1 animal / 10 000 animals treated, including isolated reports): | Hypersensitivity reaction (allergic reaction) Vomiting ¹ , soft stool ¹ Polydipsia ¹ , adipsia ¹ Hyperactivity ^{1,3} Joint cartilage disorder ² |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

¹ Mild. These signs cease spontaneously after treatment and do not necessitate cessation of treatment.

² In juvenile dogs and care should be taken to dose accurately, especially in young animals.

³ Transient.

Cats:

| | |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Very rare (<1 animal / 10 000 animals treated, including isolated reports): | Hypersensitivity reaction (allergic reaction) Vomiting ¹ , soft stool ¹ Polydipsia ¹ , adipsia ¹ Hyperactivity ¹ |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

¹ Mild. These signs cease spontaneously after treatment and do not necessitate cessation of treatment.

At the therapeutic recommended dosage, no severe side-effects are to be expected in dogs and cats.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during pregnancy and lactation.

3.8 Interaction with other medicinal products and other forms of interaction

Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron). In such cases, the bioavailability may be reduced.

3.9 Administration routes and dosage

Oral use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

The recommended dose rate is 2 mg/kg/d (1 tablet for 2.5 kg per day) in a single daily administration.

DOGS

In skin and soft tissue infections, treatment duration is at least 5 days. Depending on clinical evolution, it may be extended up to 40 days.

In lower urinary tract infections, treatment duration is at least 10 days.

In case of associated prostatitis or epididymitis or in case of upper urinary tract infections, treatment may be extended up to 28 days.

In respiratory infections, treatment duration is at least 7 days and depending on the course of the disease, it may be extended up to 21 days.

CATS

For skin and soft tissue infections (wounds, abscesses, phlegmons) treatment duration is 3 to 5 days.

For upper respiratory infections, treatment duration is 5 days.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdose may cause acute signs in the form of neurological disorders which would have to be treated symptomatically.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code : QJ01MA93

4.2 Pharmacodynamics

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci, Streptococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp., Klebsiella spp., Shigella spp., Pasteurella spp., Haemophilus spp., Moraxella spp., Pseudomonas spp., Brucella canis) as well as Mycoplasma spp.

4.3 Pharmacokinetics

After oral administration in dogs and cats at the recommended dose of 2 mg/kg, marbofloxacin is

readily absorbed and reaches maximal plasma concentrations of 1.5 µg/ml within 2 hours. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (less than 10%), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, digestive tract) it achieves higher concentrations than in plasma. Marbofloxacin is eliminated slowly ($t_{1/2\beta} = 14$ h in dogs and 10 h in cats) predominantly in the active form in urine (2/3) and faeces (1/3).

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage precautions.

5.4 Nature and composition of immediate packaging

Aluminium/aluminium thermoshaped blister strips.
Carton contains 100 tablets (10 blisters of 10 tablets).

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Vetoquinol Ireland Limited

7. MARKETING AUTHORISATION NUMBER(S)

VPA10983/054/001

8. DATE OF FIRST AUTHORISATION

19/04/2004

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

02/04/2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).